Categories
Disease Modifying Anti-rheumatic Drugs,DMARDs Golimumab Pharmacology Physiotherapy

Golimumab and Infections

In this article we will discuss Golimumab and Infections

In this article, we will discuss Golimumab and Infections. So, let’s get started.

Golimumab and Infections

In controlled Phase 3 trials through Week 16 in RA, PsA, and AS, infections were observed in 28% of Golimumab-treated patients compared to 25% of control-treated patients.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.